TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) will be releasing its earnings data before the market opens on Thursday, November 14th. Analysts expect TriSalus Life Sciences to post earnings of ($0.37) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $7.36 million during the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
TriSalus Life Sciences Trading Up 0.5 %
NASDAQ:TLSI traded up $0.02 during trading hours on Thursday, reaching $4.18. 15,310 shares of the company traded hands, compared to its average volume of 38,339. The business's 50-day moving average price is $4.46 and its two-hundred day moving average price is $6.05. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.42. The stock has a market capitalization of $122.52 million, a P/E ratio of -1.67 and a beta of 0.49.
Analyst Ratings Changes
A number of brokerages recently issued reports on TLSI. Northland Capmk upgraded shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday, October 25th. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an "outperform" rating and a $10.00 target price on the stock. Finally, Northland Securities assumed coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an "outperform" rating and a $12.50 price target on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences has an average rating of "Buy" and an average price target of $12.50.
Check Out Our Latest Research Report on TLSI
Insider Buying and Selling
In related news, CEO Mary T. Szela purchased 7,520 shares of TriSalus Life Sciences stock in a transaction on Thursday, September 12th. The shares were bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now owns 377,382 shares in the company, valued at approximately $1,962,386.40. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 32.80% of the stock is owned by company insiders.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
See Also
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
